

## Checklist for the description of sequence variants

*Last modified April 28, 2014*

*Since references to WWW-sites are not yet acknowledged as citations, please mention [den Dunnen JT and Antonarakis SE \(2000\). Hum.Mutat. 15:7-12](#) when referring to these pages.*

---

### Purpose

Going through publications one can easily see where people tend to offend the "[Current recommendations for the description of sequence variants](#)". The checklist below covers the most problematic issues and should assist those preparing a publication to describe sequence variants following the current recommendations.

---

### Checklist

1. **Reference Sequence** - do you clearly mention the reference sequence used for numbering (nucleotides/amino acids)?  
A publication should mention, preferably in the Materials & Methods section and/or Table legend, which sequence file was used as reference sequence for numbering of the residues (DNA, RNA and protein) and describing the variants; see [Recommendations](#), [Discussion](#) and [mtDNA variants](#).
  - do you mention a *GenBank* (not *GeneBank*) *RefSeq*-file accession number **with version number**?; do not forget the underscore in the accession number (correct is NM\_004006.2, not NM004006.2).
  - a genomic reference sequence starts with nucleotide 1; a genomic reference sequence can not have negative numbers
  - for a coding DNA reference sequence, do you clearly state that *nucleotide numbering uses the A of the ATG translation initiation start site as nucleotide 1*?
  - when you **do not** use a coding DNA reference sequence and **do not** start nucleotide numbering **with 1 at the A of the ATG**

translation initiation start you should not use descriptions preceded by "c".

- if legacy numbering is used, this can only be done *in addition to* the approved nomenclature.
- does your reference sequence contain introns?; not that *NM\_* reference sequences cover mature transcripts and do not contain intronic sequences.

2. **Intronic variants** - do you indicate where the *reference intron sequence* can be found ?

The recommendation is to describe *intronic variants* in the format "**c.89-2A>G**" and not like "*IVS4-2A>G*" (see [Discussion](#)). When the format "*IVS4-2A>G*" is used, it is essential to give a clear reference for *intron / exon numbering* and to mention the *reference sequence used for the intron*.

3. **Tabular overview** - do you provide a clear, unequivocal overview of all changes reported?

Preferably, a publication contains a *tabular overview* of all variants reported. This overview contains columns describing the change at *DNA-level (absolutely essential)* and, optional, at *RNA* and *protein level*. When data on RNA and/or protein level are provided, it should be made clear whether the data were *deduced or experimentally verified* (i.e. state explicitly when RNA was analysed, e.g. to study the consequences of a variant affecting splicing).

4. **Insertions**

- are insertions reported in the format c.51\_52insT?

Since it is not clear whether one means *insertion at* or *insertion after* position 52, insertions should not be reported as c.52insT but in the format c.51\_52insT (see [Discussion](#)).

- do you give the inserted sequence?

Describing a variant like c.5439\_430ins6 is *not sufficient*, the inserted sequence (ins6, e.g. TGCCAT) *should always be mentioned*.

- are the insertions reported really insertions or are they in fact duplications?

Duplicating insertions should be described as duplications, not as insertions; for the change CCAGTAAC to CCAGTGTAAC the description is c.4\_5dup (or c.4\_5dupGT) is correct, c.5\_6insGT is not correct (see [Discussion](#)).

5. **Most 3' position** - do you correctly assign the change to the most 3' (or C-terminal for protein variants) position possible?

For deletions, duplications and insertions the *most 3' position possible is arbitrarily assigned* to have been changed (see [Recommendations](#)); important especially in single residue (nucleotide or amino acid) stretches or tandem repeats. Example CCAGTGTAAC to CCAGTAAC is described as c.6\_7del (or c.6\_7delGT, not as c.3\_4del or c.4\_5del).

6. **Recessive diseases** - do you clearly describe which changes are found in which combination?

a publication describing sequence changes found in patients suffering from a recessive disease should for each patient explicitly mention which *combination of changes* was identified (see [Recommendations](#)). Example c.[76C>T];[87G>A] or c.[76C>T];[?].

**NOTE:** this description differs from that describing *several changes in one allele*, which has the format c.[76A>C;113G>C].

7. **Range** - the sign used to indicate a range is "\_" (underscore) and not a "-" (minus)?

To prevent confusion, the *underscore* should be used to indicate a *range* and not the minus sign. The *minus sign* should only be used to indicate *negative numbers*. The correct description to indicate a deletion of the coding DNA nucleotides 12 to 14 is c.12\_14del. Not correct is c.12-14del, this describes a deletion of nucleotide -14 in the intron directly preceding cDNA nucleotide 12 (see [Discussion](#)).

8. **Deletion** - do you indicate the first and last residue involved in a deletion?

A deletion of more than one residue should mention the first and last residue deleted, separated using a "\_" (underscore), e.g. c.21\_24del or p.Ala13\_Gln16del. Descriptions like c.21del3 should not be used.

## 9. Describe at DNA-level - do you describe all changes reported at DNA-level?

All changes reported must be described at DNA-level

- when descriptions at protein level are given in the text, upon first appearance, use a format like "**c.78G>C (p.(Trp26Cys), RNA not analysed)**" or "**c.78G>C (p.Trp26Cys, RNA analysed)**"
- description of "*silent variants*" in the format "p.(Leu54Leu) (or **p.(L54L)**)" **should not be used** ([see Discussion](#)). Descriptions should be given at DNA level. Descriptions like p.(Leu54Leu) are non-informative and not unequivocal (there are five possibilities at DNA level); a correct description is **c.162C>G**

## 10. RNA protein level descriptions

Recommendations exist to describe alternative transcripts deriving from one allele (see [Recommendations](#)). Since these descriptions may be rather complex to explain, it is wise to include a link to the HGVS recommendations in the publication.

## 11. Protein level descriptions

- **protein reference sequence** - the protein reference sequence should represent the primary translation product, not a processed mature protein, and thus include any signal peptide sequences (see [Recommendations](#)).
- **NEW: Ter / \*** - do you use Ter or \* to indicate a translation stop codon; the X is not allowed anymore (see [Important changes](#))
- **one/three letter amino acid code** - are the correct amino acid codes used at protein level?; several amino acids start with the same initial letter (Ala, Arg, Asn, Asp start with **A**, Gln, Glu, Gly with **G**, Leu, Lys with **L**, Phe, Pro with **P** and Thr, Tyr with **T**) but that initial letter is used as one-letter-amino-acid-code for only one of these (see [Discussion](#) and [Codons and amino acids](#))
- **initiating methionine (Met1)** - **p.Met1?** denotes that amino acid Methionine-1 (translation initiation site) is changed and that it is unclear what the consequence of this change is. When experimental data show that no protein is made, the description **p.0** should be used. The description p.Met1Val is not allowed (see [Discussion](#))
- **no-stop change** - recommendations have recently been made to describe substitutions in the stop codon, so called **no-stop changes** like p.\*110Tyrext\*16 (see [Recommendations](#))

## 12. Polymorphisms

Do not describe polymorphic variants as c.127A/G (or p.43I/V). A description of a variant should be **neutral** and polymorphisms and pathogenic changes should not be described differently (see [Discussion](#)). Correct descriptions are c.127A>G and p.(Ile43Val).

---

| [Top of page](#) | [MutNomen homepage](#) |  
| **Recommendations:** [DNA](#), [RNA](#), [protein](#), [uncertain](#) |  
| [Discussions](#) | [FAQ's](#) | [Symbols, codons, etc.](#) | [History](#) |  
| **Example descriptions:** [QuickRef / symbols](#), [DNA](#), [RNA](#), [protein](#) |